ClinicalTrials.gg
RecruitingNCT07084597Updated Jul 29, 2025

Effect of Vitamin D3 Supplementation on Cardiac Autonomic Nerve Function in Male Parkinson's Disease Patients With Hypovitaminosis D

An interventional study of Vitamin D in Parkinson Disease, sponsored by Bangladesh Medical University. Recruiting at 1 site in Bangladesh. Open to male participants aged 51 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by Bangladesh Medical University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
51 Years to 70 Years
Sex
Male
01

Study summary

The goal of this clinical trial is to see the effect of vitamin D3 supplementation on cardiac autonomic nerve function in male Parkinson's disease patients with hypovitaminosis D

Main questions it aims to answer are:

  1. Does vitamin D improves heart rate variability(HRV) in male Parkinson's disease patients ?
  2. Does vitamin D improves cardiac autonomic nerve function in male Parkinson's disease patients ? It is a self control trial. Vitamin D3 deficient Parkinson's disease participants will

a. undergo through baseline HRV test b. Then they will take vitamin D3 capsule 50000 IU once in a week for 8 consecutive weeks c. Then after intervention with vitamin D supplementation post interventional HRV will be done.

Researcher will compare pre intervention(pre test) and post intervention(post test) value of HRV

Read the detailed description

In Parkinson's disease , there is a shifting of autonomic nerve function towards sympathetic dominance and Heart rate variability decrease. Reduced heart rate variability can be detected by Heart rate variability(HRV) testing.

In Parkinson's disease deposition of Lewy bodies (due to accumulation of alpha- synuclein protein ) causes degeneration of dopaminergic neuron. Parasympathetic nerve results from vagus nerve atrophy and simultaneous sympathetic denervation results in decrease HRV.

Hypovitaminosis D is commonly associated with Parkinson's disease due to alteration of gastrointestinal function, progressive skin atrophy, lack of mobilization, lack of sun exposure.

Vitamin D3 act as neuroprotective hormone and plays role in autonomic nervous system regulation and maintaining balance between sympathetic and parasympathetic nervous system. Vitamin D3 deficiency is associated with cardiac autonomic imbalance. Administration of vitamin D3 in vitamin D deficient Parkinson's patient may may improve cardiac autonomic nerve function that can be interpreted by HRV.

02

Conditions studied

  • Parkinson Disease

Keywords

  • Vitamin D3
  • HRV
  • Hypovitaminosis D
  • Parkinson disease
03

In context

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

This study's planned enrollment of 15 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Bangladesh Medical University is the lead sponsor of 46 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
51 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

IInclusion criteria:

  • Male patients with of Parkinson's disease diagnosed by neurologist with unilateral or bilateral involvement and mild to moderate disability according to Hoehn and Yahr (H-Y) scale (I-III)
  • Age: 51-70 years
  • : 18.5-24.9 kg/m2
  • Vitamin D3 deficient or insufficient
  • On Levodopa medication

Exclusion criteria:

  1. Patients with a history of drug abuse including alcoholism.
  2. Patients on following drugs will be excluded-

    • Antioxidant vitamin supplements
    • Lipid lowering medications
    • Antihypertensive drug
    • Anti-arrhythmic drug
    • Sedatives
  3. All patients with the history of or clinical manifestation of currently suffering from following diseases \& condition will be excluded

    • Severe Cardiovascular disorders
    • Severe neurological disorders
    • Severe Respiratory disorders
    • Severe Renal insufficiency (S. Creatinine > 1.5 mg/dl, Acute or chronic kidney disease)
    • Severe Endocrine disease
    • Severe Arthritis
    • Severe Liver diseases
    • Severe Neoplastic disease
    • Severe Psychiatric disorder
    • Current use of iron, zinc, calcium, magnesium and multivitamin supplementation
    • Already performing yoga or breathing exercise
    • Hypercalcemia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    15 male Parkinson's disease patients

    15 male Parkinson's disease patients with hypovitaminosis D will be enrolled. They will be supplemented with vitamin D orally 50,000 IU/weeks for 8 weeks

    Dietary Supplement: Vitamin D

Interventions

  • Dietary supplementVitamin D

    Vitamin D ,50000 IU/week will be given for 8 consecutive weeks

06

What researchers measure

Primary outcomes

  1. Vitamin D3 supplementation has effect on cardiac autonomic nerve function in male Parkinson's disease patient

    Altered cardiac autonomic nerve function

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
  • Bangladesh Medical University
    Dhaka, Shahbag 1000, Bangladesh
    Recruiting
    • Jobayda Jobayda, MBBS,MD(Phase B) · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Oct 2025, 3 months later.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 3 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2025
First posted
Jul 24, 2025
StartEst.
Jul 2025
Primary completionEst.
Oct 2025
CompletionEst.
Oct 2025
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07084597
Lead sponsor
Bangladesh Medical University
Responsible party
Jobayda Binte Rahmatullah (MD Resident, Bangladesh Medical University) — Principal investigator
First posted
Jul 24, 2025
Start date
Jul 2025 (estimated)
Primary completion
Oct 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
Jul 29, 2025

Study contacts

Registrar BMU
Contact
registrar@bsmmu.edu.bd
+880255165708 ext. 94
Jobayda Jobayda, MBBS,MD resident,Phase B
Contact
jbinterohmotullah@gmail.com
01773845305

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vitamin D

Start the discussion